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Abstract
Background: Chronic obstructive pulmonary disease (COPD) is a heterogeneous syndrome characterized by
varying degrees of airflow limitation and diffusion impairment. There is increasing evidence to suggest that COPD
is also characterized by systemic inflammation. The primary goal of this study was to identify soluble proteins in
plasma that associate with the severity of airflow limitation in a COPD cohort with stable disease. A secondary
goal was to assess whether unique markers associate with diffusion impairment, based on diffusion capacity of
carbon monoxide (DLCO), independent of the forced expiratory volume in 1 second (FEV1).
Methods: A cross sectional study of 73 COPD subjects was performed in order to examine the association of
25 different plasma proteins with the severity of lung function impairment, as defined by the baseline
measurements of the % predicted FEV1 and the % predicted DLCO. Plasma protein concentrations were assayed
using multiplexed immunobead-based cytokine profiling. Associations between lung function and protein
concentrations were adjusted for age, gender, pack years smoking history, current smoking, inhaled
corticosteroid use, systemic corticosteroid use and statin use.
Results:  Plasma concentrations of CCL2/monocyte chemoattractant protein-1 (CCL2/MCP-1), CCL4/
macrophage inflammatory protein-1β (CCL4/MIP -1β), CCL11/eotaxin, and interleukin-13 (IL-13) were inversely
associated with the % FEV1. Plasma concentrations of soluble Fas were associated with the % DLCO, whereas
CXCL9/monokine induced by interferon-γ (CXCL9/Mig), granulocyte- colony stimulating factor (G-CSF) and IL-
13 showed inverse relationships with the % DLCO.
Conclusion: Systemic inflammation in a COPD cohort is characterized by cytokines implicated in inflammatory
cell recruitment and airway remodeling. Plasma concentrations of IL-13 and chemoattractants for monocytes, T
lymphocytes, and eosinophils show associations with increasing severity of disease. Soluble Fas, G-CSF and
CXCL9/Mig may be unique markers that associate with disease characterized by disproportionate abnormalities
in DLCO independent of the FEV1.
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Background
Chronic obstructive pulmonary disease (COPD), while
defined by the presence of incompletely reversible airflow
obstruction, represents a syndrome of various physiologic
impairments [1,2]. COPD is also defined by "an abnor-
mal inflammatory response to noxious stimuli" [1,2], and
increasing evidence suggests that COPD is a disease char-
acterized by both local and systemic inflammation [3].
The best characterized systemic marker is C-reactive pro-
tein (CRP) [3,4], but its lack of specificity provides little
insight into potential mechanisms underlying the sys-
temic inflammation characterizing COPD. We hypothe-
size that this systemic inflammation may be further
characterized by examining associations between physio-
logic indices of lung function impairment and members
of various classes of soluble proteins. To date, studies
examining the association between a wide range of solu-
ble proteins in plasma and severity of lung function
impairment during stable COPD are lacking. This is due,
in part, to the limited amount of sample that can be
obtained from subjects at any given time.
We conducted an exploratory analysis to determine the
associations between increasing physiologic severity of
COPD, as defined by the % predicted FEV1 or % DLCO,
during stable disease and plasma concentrations of 25 dif-
ferent cytokines and growth factors. We adjusted for cur-
rent cigarette smoking and corticosteroid use because
others have shown that these factors may be potential
modifiers of systemic inflammation in this cohort [5-7].
We also adjusted for variables such as gender, age, statin
use, and pack years smoking that may influence cytokine
levels. This analysis represents an important, initial stage
in identifying candidate plasma proteins for future pro-
spective, longitudinal studies and one that utilizes a new
technique to assay for multiple cytokines at a given time.
Methods
Patient selection
Seventy-three individuals enrolled in the Emphysema/
COPD Research Center (ECRC) of the University of Pitts-
burgh gave informed consent for the study. Inclusion cri-
teria included clinically stable COPD at the time of the
examination, tobacco exposure of at least 10 pack years,
and no clinical diagnosis of rheumatologic, infectious or
other systemic inflammatory disease. Exclusion criteria
included dominant restrictive spirometric impairment, a
significant allergic history, completely reversible airflow
obstruction or a history of clinical asthma. The study was
approved by the University of Pittsburgh Institutional
Review Board.
Pulmonary function measurements
Spirometry was performed on 73 subjects using standard
methodology at the time of entry into the study [8-10].
Fifty-three subjects also had single breath carbon monox-
ide diffusing capacity using standard methodology [11].
Standard reference equations for % FEV1 and % DLCO
were used [12,13].
Plasma marker measurements
Plasma samples were obtained from subjects upon enroll-
ment into the ECRC registry. Blood was collected into acid
citrate dextrose (ACD) cell preparation tubes (CPT tubes).
Samples were processed immediately, and plasma was
isolated and stored immediately at -80°C until analyzed.
A detailed methods of the multiplex assay performed at
the University of Pittsburgh Cancer Institute Luminex
Core Facility has been previously described [14]. We have
previously used a multiplex immuno-bead assay system
(Luminex, Austin, TX, USA) to assay multiple systemic
cytokine concentrations using both mouse and human
plasma samples [15]. Reproducibility of cytokine signals
for inter-individual comparisons using stimulated plasma
samples has been previously demonstrated using the mul-
tiplex format [16]. Four sets of plates were used to assay a
total of 28 cytokines and inflammatory markers: Set 1)
Twenty-three cytokines in multiplex format (Biosource
Invitrogen, Camarillo, CA); Set 2) EGFR, Fas, and FasL
analytes in multiplex format (University of Pittsburgh
Luminex Core Facility, Pittsburgh, PA); Set 3) CRP con-
centrations (LINCO Research, St. Charles, Missouri); Set
4) MPO concentrations (LINCO Research, St. Charles,
Missouri). All samples were assayed simultaneously to
minimize day-to-day variability (Table 1).
Selection of specific cytokines in the study was based
upon two main criteria: (1) availability of reagent using
the Luminex platform, and (2) prior published data to
suggest biological plausibility of a cytokine or soluble
protein in either systemic or local inflammation observed
in COPD. We chose six broad classes of soluble proteins
and measured representative markers (Table 1). Apopto-
sis-related proteins included soluble Fas, FasL, soluble
TNFRI and TNFRII [17-19]. Acute phase reactants
included C-reactive protein (CRP) [4] and Myeloperoxi-
dase (MPO) [20]. Representative chemokines included
CCL2/MCP-1, CCL3/MIP-1α and CCL4/MIP-1β [21],
CCL5/RANTES [22], CCL11/eotaxin [23], CXCL8/IL-8
[24,25], and CXCL9/Mig [26]. TH related cytokines were
also of considerable interest, given recent findings regard-
ing the role of the TH phenotype in COPD [27-29]. Repre-
sentative TH1 and TH2 cytokines interferon-gamma (IFN-
γ), interleukin-2 (IL-2) and its soluble receptor IL-2R,
interleukin-4 (IL-4), and IL-13 were chosen on this basis.
Inflammation related proteins included TNF-α [30,31],
soluble TNFR1 and TNFRII [30,31], IL-1β [32], IL-6 [32],Respiratory Research 2007, 8:64 http://respiratory-research.com/content/8/1/64
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and IL-10 [28]. Growth factors included epidermal
growth factor (EGF) and its soluble receptor epidermal
growth factor receptor (EGFR) [33-35], fibroblast growth
factor beta (FGFβ) [36,37], granulocyte-colony stimulat-
ing factor (G-CSF)[38], hepatocyte growth factor (HGF)
[39], and vascular endothelial growth factor (VEGF) [40].
Standard curves were generated according to the manufac-
turer's instructions. Goodness of fit for standard curves
was determined by the standards recovery method and
performed by calculating the following equation for the
concentration of each standard: (observed concentration/
expected concentration) × 100. Concentrations for the
unknown samples were calculated based upon a 5 para-
metric curve fitting program (Bio-Rad Laboratories, Her-
cules, CA). The 5 parametric curve fitting program yields
extrapolated values beyond the concentrations for a given
standard curve as determined by conventional linear
regression, and is the preferred mathematical modeling
for multiplex immunoassays [41,42]. This provided a
greater detectable range of observed concentrations, and
was particularly useful for analytes where plasma concen-
trations of samples were uniformly low.
We defined the lower limit of detection (LLD) for each
analyte as the lowest observed concentration in pg/mL.
This was, in some instances, an extrapolated value that
was lower than the lowest standard curve concentration.
Unknown sample concentrations, below the LLD for a
given analyte, were assigned a value set just below the LLD
using the following equation: undetectable value = LLD of
analyte/squared root 2. This method of assigning a value
for unknown sample concentrations with undetectable
levels has been previously used to examine the relation-
ship of impaired lung function to circulating levels of C-
reactive protein and fibrinogen [4]. This allowed for the
inclusion of all samples in our analysis, with data shown
in Table 1.
Statistical analysis
We performed univariate and multivariate linear regres-
sion analysis to test the association between the concen-
tration of each plasma cytokine and the physiologic
indices of interest: percent (%) predicted FEV1 and the %
predicted DLCO. The dependent variable of interest,
plasma cytokine concentration, was not normally distrib-
uted; thus, values were log transformed to meet the
assumption of normality for linear regression. Standard
regression diagnostics were performed to ensure the
assumptions for linear regression were met. Covariates
previously published as associated with the outcomes of
interest (e.g. current smoking and corticosteroid use) were
identified  a priori and also included [5-7]. We also
included variables presumed to alter cytokine values: age,
gender, statin use, and pack year smoking history. Statisti-
cal significance was determined at a p-value < 0.05. We
did not attempt to adjust for multiple comparisons as our
emphasis, being exploratory, was to minimize a Type I
error and any adjustment could potentially miss real dif-
ferences within the scope of this modest sample size [43].
SAS 8.2 (SAS Institute Inc., Cary, NC) and STATA 9.0
(Stata Corporation, College Station, Texas) softwares were
used for analysis.
Results
Subject demographics
Seventy-three individuals were recruited for analysis.
Table 2 shows the subject demographics for each Global
Table 1: Detectability of plasma marker concentrations
Classification Plasma 
marker
Mean (pg/mL) 
+ SE
LLD* 
(pg/mL)
below 
LLD (%)
Apoptosis Fas 74 ± 3 1.3 0
FasL 68 ± 4 6.5 0
Acute phase CRP 6268332 ± 
1124813
78 0
MPO 4381 ± 589 13 3
Chemokines CCL2/
MCP -1
202 ± 6 10 0
CCL3/
MIP-1α
161 ± 33 6.8 5
CCL4/
MIP-1β
115 ± 20 1.3 1
CCL5/
RANTES
5249 ± 398 8.2 0
CCL11/
eotaxin
76 ± 3 2.3 0
CXCL8/
IL-8
11 ± 0.4 6.1 0
CXCL9/
Mig
1163 ± 87 35 0
TH Related 
Cytokines
IFN-γ 55 ± 7 2.1 8
IL-2 103 ± 23 2.6 23
IL-2R† 344 ± 28 39 0
IL-4 15 ± 3 0.6 25
IL-13 98 ± 7 8.2 11
Inflammation TNF-α 55 ± 7 5.3 0
TNFRI† 1352 ± 95 36 0
TNFRII† 3231 ± 138 39 0
IL-1β 72 ± 17 8.5 45
IL-6 19 ± 4 0.4 1
IL-10 0.3 ± 0.08 0.2 96
Growth 
Factors
EGF 19 ± 1.5 2.5 0
EGFR† 19769 ± 434 13.5 0
FGFβ NE‡ NE‡ NE‡
G-CSF 2496 ± 180 379 0
HGF 196 ± 9 2.8 0
VEGF NE‡ NE‡ NE‡
*LLD, Lower Limit of Detection
†For clarity, the soluble receptors are grouped with their respective 
ligand
‡NE, Not EvaluableRespiratory Research 2007, 8:64 http://respiratory-research.com/content/8/1/64
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initiative for Chronic Obstructive Lung Disease (GOLD)
classification. The prevalence of cigarette smoking
decreased and the use of inhaled or systemic corticoster-
oids increased with more severe airflow obstruction.
Fifty-three of the 73 individuals from the cohort received
DLCO measurements (Table 3). We addressed the poten-
tial for selection bias by comparing the patient character-
istics of those with and without DLCO measurements.
There was no significant difference between those with
and those without DLCO measurements for any of the
patient characteristics.
Detectability of plasma protein concentrations
Twenty-eight markers from 6 classes of soluble proteins
were originally measured. The mean plasma concentra-
tions in pg/mL are depicted in Table 1. Sixteen of 28 pro-
teins showed detectable concentrations for all samples
(Table 1). Ten of 28 proteins were below the detectable
range for some samples (MPO, CCL3/MIP-1α, CCL4/
MIP-1β, IFN-γ, IL-2, IL-4, IL-13, IL-1β, IL-6, IL-10). None
of the samples were above the detectable range for any of
the proteins measured. IL-10 concentrations were unde-
tectable in virtually all patients (70/73, 96%), and stand-
ard curves generated for FGFβ and VEGF were consistently
poor. Thus, IL-10, FGFβ, and VEGF were excluded from
further analysis, and a total of 25 cytokines were assessed
for an association with severity of lung function impair-
ment.
Association between systemic cytokines and FEV1
In univariate analyses, increasing concentrations of T
helper (TH) related cytokines interferon-γ (IFN-γ), inter-
leukin-2 (IL-2), interleukin-4 (IL-4) and IL-13 were asso-
ciated with increasing severity of airflow obstruction, as
characterized by decreasing % predicted FEV1 (Table 4).
Increasing concentration of the monocyte and T lym-
phocyte chemokine CCL4/MIP-1β was also associated
with increasing severity of airflow obstruction (Table 4).
We did not observe significant associations between
plasma CRP concentrations and the % predicted FEV1. We
explored the effect of inhaled corticosteroids on the rela-
tionship between CRP and the % FEV1because of previous
findings that inhaled corticosteroids can suppress sys-
temic CRP levels [6]. In contrast to other cytokines exam-
ined, we noted interaction between corticosteroids with
CRP concentrations (p = 0.05). An overall association was
not observed between increasing plasma CRP with
increasing severity of airflow limitation because the mag-
nitude of the difference in CRP concentration across %
FEV1 was diminished in those with corticosteroid use as
compared to those without (data not shown).
Multivariate model of the association between systemic 
cytokines and FEV1
After adjusting for age, gender, pack years smoking his-
tory, current smoking, inhaled corticosteroid use, sys-
Table 3: Demographics, comparison of subjects with and 
without % DLCO measurements
Subjects with 
DLCO
Subjects 
without DLCO
p-value
Sample size 53 20 -
Age, years* 64 (1) 61 (2) 0.16
Sex, M/F 32/21 10/10 0.43
Pack years* 54 (3) 49 (5) 0.49
Current 
smokers (%)
15 (28) 4 (20) 0.48
ICS use (%) 24 (45) 12 (60) 0.27
SCS use (%) 3 (6) 2 (10) 0.52
% FEV1 * 5 1  ( 4 )5 1  ( 6 )0 . 9 7
FEV1/ F V C * 4 5  ( 2 )4 6  ( 4 )0 . 8 9
*Data are presented as mean (SEM).
Table 2: Demographics, comparison of subjects by GOLD classification
GOLD 0 GOLD 1 GOLD 2 GOLD 3 GOLD 4 Total
S a m p l e  s i z e 5 8 2 12 01 97 3
Age, years* 61 (2) 59 (2) 64 (2) 67 (2) 60 (2) 63 (1)
Sex, M/F 3/2 5/3 12/9 13/7 9/10 42/31
P a c k  y e a r s * 3 7  ( 4 )5 7  ( 8 )6 0  ( 7 )5 3  ( 4 )4 7  ( 4 )5 3  ( 3 )
Current smokers 
(%)
2 (40) 4 (50) 7 (33) 5 (25) 1 (5) 19 (26)
ICS use (%) 0 (0) 1 (13) 7 (33) 12 (60) 16 (84) 36 (49)
SCS use (%) 0 (0) 0 (0) 0 (0) 2 (10) 3 (16) 5 (7)
% FEV1 * 8 7  ( 4 )9 1  ( 3 )6 6  ( 2 )3 9  ( 1 )2 1  ( 1 )5 1  ( 3 )
FEV1/FVC* 77(2) 63 (2) 55 (2) 37 (2) 28 (1) 45 (2)
% DLCO* † 6 8  ( 4 )5 8  ( 7 )6 2  ( 4 )3 7  ( 2 )2 5  ( 1 )4 6  ( 3 )
ICS, inhaled corticosteroids; SCS, systemic corticosteroids
*Data are presented as mean (SEM)
†DLCO % predicted measurements not available for 1 subject in GOLD 0, 2 subjects in GOLD 1, 6 subjects in GOLD 2, 6 subjects in GOLD 3, 5 
subjects in GOLD 4.Respiratory Research 2007, 8:64 http://respiratory-research.com/content/8/1/64
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temic corticosteroid use and statin use, three of the seven
chemokines examined were significantly associated with
% FEV1 (Table 5). Increasing concentrations of chemok-
ines CCL4/MIP-1β, CCL2/MCP-1, and CCL11/eotaxin
were associated with increasing severity of airflow
obstruction. Of the 4 TH related cytokines that showed
associations with % FEV1 in univariate analysis (Table 4),
only IL-13 remained significant (Table 5). Thus, CCL4/
MIP-1β and IL-13 showed inverse associations with %
FEV1 both by univariate and multivariate analysis.
Association between systemic cytokines and DLCO
We examined the association between systemic cytokines
and the % predicted DLCO (Table 6). Increasing concen-
trations of chemokines CCL4/MIP -1β, CC chemokine lig-
and 5/Regulated on Activation Normal T cell Expressed
and Secreted (CCL5/RANTES), CXC chemokine ligand 8/
interleukin 8 (CXCL8/IL-8), and CXCL9/Mig were associ-
ated with increasing severity of diffusion impairment, as
characterized by decreasing % predicted DLCO. Similar to
FEV1, TH related cytokines IFN-γ, IL-2, IL-4 and IL-13
showed inverse associations with the % predicted DLCO.
We also observed that increasing concentrations of TNF-α,
epidermal growth factor (EGF) and G-CSF associated with
increasing severity of diffusion impairment. This is in con-
trast to soluble Fas where lower concentrations were asso-
ciated with increasing severity of diffusion impairment.
Systemic markers such as CRP, IL-6 and MPO did not
show significant associations with the % predicted DLCO.
Multivariate model of the association between systemic 
cytokines and DLCO
We further examined the relationship between plasma
concentrations of inflammatory markers and the % pre-
dicted DLCO, adjusting for the % FEV1, age, gender, pack
years smoking history, current smoking, inhaled corticos-
teroid use, systemic corticosteroid use and statin use
(Table 7). The inverse associations between % DLCO and
CXCL9/Mig, G-CSF, and IL-13 remained significant. The
association between soluble Fas and % DLCO also
remained significant.
IL-13 and Bronchodilator Reversiblity
Of the 25 cytokines examined, increasing plasma concen-
trations of IL-13 showed inverse relationships with both
% FEV1 and % DLCO (Figures 1 &2). We tested the possi-
bility that a subset of the population with bronchodilator
Table 5: Association between plasma markers and % FEV1, 
adjusted*
Analyte β† 95% CI p‡
CCL2/MCP -1 -0.003 -0.005, -0.001 0.02
CCL4/MIP-1β -0.01 -0.02, -0.001 0.04
CCL11/eotaxin -0.005 -0.01, -0.002 0.004
CXCL9/Mig -0.01 -0.02, 0.0003 0.06
EGF -0.005 -0.01, 0.004 0.24
IFN-γ -0.01 -0.03, 0.002 0.08
IL-2 -0.02 -0.03, 0.004 0.12
IL-2R -0.005 -0.01, 0.002 0.15
IL-4 -0.02 -0.03, 0.001 0.07
IL-13 -0.01 -0.02, -0.001 0.04
*Adjusted for current smoking, pack years, ICS use, SCS use, statin 
use, gender and age.
†β = regression co-efficient
‡p = p-value
Table 4: Association between plasma marker concentrations and 
% FEV1, unadjusted
Classification Plasma 
marker
β† 95% CI p‡
Apoptosis Fas 0.003 -0.001, 0.01 0.12
FasL 0.001 -0.004, 0.01 0.67
Acute phase CRP -0.01 -0.02, 0.003 0.19
MPO 0.0004 -0.01, 0.01 0.93
Chemokines CCL2/
MCP -1
-0.002 -0.004, 0.001 0.14
CCL3/
MIP-1α
-0.004 -0.02, 0.01 0.53
CCL4/
MIP-1β
-0.01 -0.02, -0.003 < 
0.01
CCL5/
RANTES
-0.005 -0.01, 0.002 0.18
CCL11/
eotaxin
-0.003 -0.006, 0.0004 0.09
CXCL8/
IL-8
-0.002 -0.01, 0.001 0.18
CXCL9/
Mig
-0.01 -0.01, 0.001 0.09
THRelated 
Cytokines
IFN-γ -0.01 -0.03, -0.001 0.04
IL-2 -0.02 -0.04, -0.002 0.03
IL-2R§ -0.005 -0.01, 0.0003 0.06
IL-4 -0.02 -0.03, -0.003 0.02
IL-13 -0.01 -0.02, -0.0004 0.04
Inflammation TNF-α -0.01 -0.02, 0.002 0.11
TNFRI§ -0.001 -0.01, 0.004 0.72
TNFRII§ -0.001 -0.01, 0.004 0.83
IL-1β -0.01 -0.02, 0.01 0.47
IL-6 -0.003 -0.01, 0.01 0.61
IL-10 -0.001 -0.01, 0.004 NE*
Growth Factors EGF -0.01 -0.01, 0.001 0.09
EGFR§ 0.001 -0.001, 0.003 0.25
FGFβ NE* NE* NE*
G-CSF -0.003 -0.01, 0.002 0.28
HGF -0.002 -0.01, 0.001 0.20
VEGF NE* NE* NE*
†β = regression co-efficient
‡p = p-value
§For clarity, the soluble receptors are grouped with their respective 
ligand
*NE, Not EvaluableRespiratory Research 2007, 8:64 http://respiratory-research.com/content/8/1/64
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reversibility may account for the inverse association
between IL-13 and % FEV1. Of those subjects with availa-
ble information, 12 out of the 73 subjects in the cohort
met ATS/ERS task force definition for bronchodilator
response [44]. Excluding these 12 individuals did not alter
the association between IL-13 and % FEV1 (β = -0.01, p =
0.01). An additional 15 out of the 73 subjects did not have
bronchodilator reversibility testing at the time of study
entry, although 10 of these subjects had emphysema by
CT scan and/or abnormally low % predicted DLCO. Fur-
ther excluding these 15 individuals with unknown bron-
chodilator response from the cohort, the point estimates
for the association between IL-13 and % FEV1 in the
remaining 46 subjects was essentially unchanged but did
not reach significance due to greater variation (β = -0.01,
p = 0.06).
Discussion
We examined the association between 25 different plasma
markers of inflammation and two physiologic parameters
of COPD in a well-defined clinical population. The main
observation was that increasing severity of airflow limita-
tion, as defined by the % FEV1, was associated with
increasing systemic concentrations of IL-13, and the
inflammatory chemokines CCL2/MCP-1, CCL4/MIP-1β,
and CCL11/eotaxin after adjusting for age, gender, pack
years smoking history, current smoking, inhaled corticos-
teroid use, systemic corticosteroid use and statin use. Fur-
thermore, increasing severity of diffusion impairment, as
defined by the % DLCO, was associated with increasing
IL-13, CXCL9/Mig, and G-CSF concentrations and
decreasing soluble Fas concentrations.
In both univariate and multivariate analysis, increasing
plasma concentration of the T helper 2 (TH2) type
cytokine IL-13 was associated with increasing severity of
airflow obstruction, suggesting that IL-13 may be an
important mediator in human COPD. The association
between increasing IL-13 concentrations and increasing
severity of airflow obstruction could not be accounted for
by a subset of the cohort with bronchodilator reversibility.
This finding suggests that the association is unlikely due
to misclassification of asthmatic patients in our COPD
cohort.
IL-13 is implicated in airway mucin production and air-
way inflammation [45,46]. IL-13 has been previously
shown to induce mucous metaplasia and chemokine
expression in animal models of allergic airway inflamma-
tion and emphysema [47,48]. Others have recently shown
that both CD4+ and CD8+ T cells in the bronchoalveolar
lavage fluid of COPD patients expressed significantly
higher percentages of IL-13 than smokers with normal
lung function and never smokers [28]. Similar to our find-
The relationship between natural log (LN) IL-13 concentra- tions in pg/mL and % predicted DLCO Figure 2
The relationship between natural log (LN) IL-13 concentra-
tions in pg/mL and % predicted DLCO. The line was calcu-
lated using conditional standardization of the regression 
results for a patient with mean and modal values for the cov-
ariates in the model. The standardized line thus represents 
the relationship between IL-13 and DLCO for a man, age 63, 
with a FEV1 of 51 % predicted, who does not currently 
smoke, with mean pack year smoking history of 52.5 years, 
who is not on statins or systemic steroids, but is on inhaled 
steroids (β = -0.02).
The relationship between natural log (LN) IL-13 concentra- tions in pg/mL and % predicted FEV1 Figure 1
The relationship between natural log (LN) IL-13 concentra-
tions in pg/mL and % predicted FEV1. The line was calculated 
using conditional standardization of the regression results for 
a patient with mean and modal values for the covariates in 
the model. The standardized line thus represents the rela-
tionship between IL-13 and FEV1 for a man, age 63, who does 
not currently smoke, with mean pack year smoking history of 
52.5 years, who is not on statins or systemic steroids, but is 
on inhaled steroids (β = -0.01).Respiratory Research 2007, 8:64 http://respiratory-research.com/content/8/1/64
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ings, these authors showed a negative correlation between
intracellular IL-13 and % FEV1.
Three of seven chemokines tested were associated with
increasing severity of airflow obstruction: CCL2/MCP-1,
CCL4/MIP-1β, and CCL11/Eotaxin. In addition, CXCL9/
Mig was associated with increasing severity of diffusion
impairment. These chemokines recruit primarily mono-
cytes, T lymphocytes, and eosinophils, inviting the possi-
bility that soluble proteins that promote inflammatory
cell recruitment contribute to the low-grade systemic
inflammation observed in COPD. CCL2/MCP-1 recruits
monocytes and T lymphocytes expressing the receptor
CCR2 [49], and increased concentrations of this chemok-
ine have been reported in induced sputum, BAL and lung
tissue of COPD individuals [38,50]. CCL4/MIP-1β can
recruit CCR5 expressing monocytes and T lymphocytes
[49]. Our data corroborates findings showing a negative
correlation between CCL4/MIP-1β concentrations in the
BAL from patients with chronic bronchitis and the % FEV1
[21]. CCL11/Eotaxin is involved in eosinophil recruit-
ment [51], and CCL11/eotaxin concentrations are
increased in the sputum of patients with exacerbations of
chronic bronchitis [23]. However, some COPD patients
with stable disease also show airway eosinophilic inflam-
mation [52].
A secondary goal of this study was to explore whether sys-
temic cytokines are associated with severity of diffusion
impairment, the physiologic parameter that corresponds
best to the loss of alveolar-capillary bed surface area in
emphysema. In the smaller cohort that received DLCO
measurements, it is interesting that CXCL9/Mig concen-
tration was inversely associated with % DLCO. CXCL9/
Mig recruits CXCR3 expressing T lymphocytes [49]. Saetta
and colleagues have previously shown increased numbers
of CXCR3 expressing T lymphocytes in peripheral airways
of COPD patients [53]. Upon stimulation with CXCL9/
Mig, CD14+ CXCR3+ macrophages of human emphysema-
tous lungs can increase metalloproteinase production in
vitro [26]. Thus, recent findings suggest a potential link
between this chemokine and the pro-elastolytic environ-
ment #of emphysema.
Increasing concentrations of plasma G-CSF are also asso-
ciated with increasing severity of diffusion impairment. G-
CSF is involved in neutrophil mobilization and survival
Table 7: Association between plasma markers and % DLCO, 
adjusted*
Analyte β† 95% CI p‡
CCL2/MCP-1 -0.001 -0.01, 0.003 0.58
CCL4/MIP-1β 0.004 -0.02, 0.03 0.76
CCL5/RANTES -0.01 -0.03, 0.003 0.11
CCL11/eotaxin -0.005 -0.01, 0.002 0.15
CXCL8/IL-8 -0.004 -0.01, 0.002 0.18
CXCL9/Mig -0.02 -0.03, -0.002 0.02
EGF -0.01 -0.03, 0.01 0.29
Fas 0.01 0.003, 0.02 0.01
G-CSF -0.01 -0.02, -0.0001 0.05
HGF -0.0001 -0.01, 0.01 0.99
IFN-γ -0.02 -0.05, 0.01 0.11
IL-2 -0.03 -0.06, 0.01 0.11
IL-2R 0.01 -0.01, 0.02 0.46
IL-4 -0.02 -0.05, 0.02 0.30
IL-13 -0.02 -0.03, -0.002 0.03
TNF-α -0.01 -0.03, 0.003 0.11
*Adjusted for % FEV1, current smoking, pack years, ICS use, SCS use, 
statin use, gender and age.
†β = regression co-efficient
‡p = p-value
Table 6: Association between plasma marker concentrations and 
% DLCO, unadjusted
Classification Plasma 
marker
β† 95% CI p‡
Apoptosis Fas 0.01 0.001, 0.01 0.01
FasL -0.0004 -0.007, 0.006 0.89
Acute phase CRP -0.01 -0.02, 0.01 0.33
MPO -0.005 -0.01, 0.004 0.30
Chemokines CCL2/MCP -1 -0.003 -0.01, 0.0004 0.09
CCL3/MIP-1α 0.001 -0.02, 0.02 0.92
CCL4/MIP-1β -0.02 -0.03, -0.001 0.04
CCL5/
RANTES
-0.01 -0.02, -0.002 0.02
CCL11/
eotaxin
-0.002 -0.01, 0.002 0.31
CXCL8/IL-8 -0.005 -0.01, -0.002 < 0.01
CXCL9/Mig -0.01 -0.02, -0.004 < 0.01
THRelated 
Cytokines
IFN-γ -0.03 -0.04, -0.01 < 
0.001
IL-2 -0.04 -0.06, -0.02 < 0.01
IL-2R§ -0.005 -0.01, 0.002 0.18
IL-4 -0.03 -0.06, -0.01 < 0.01
IL-13 -0.02 -0.03, -0.01 < 
0.001
Inflammation TNF-α -0.02 -0.03, -0.005 < 0.01
TNFRI§ 0.001 -0.01, 0.01 0.79
TNFRII§ 0.001 -0.004, 0.005 0.84
IL-1β -0.01 -0.03, 0.004 0.13
IL-6 -0.01 -0.02, 0.004 0.17
IL-10 -0.01 -0.01, 0.003 NE*
Growth 
Factors
EGF -0.01 -0.02, 0.0001 0.05
EGFR§ 0.002 -0.001, 0.005 0.12
FGFβ NE* NE* NE*
G-CSF -0.01 -0.02, -0.002 0.02
HGF -0.005 -0.01, 0.001 0.08
VEGF NE* NE* NE*
†β = regression co-efficient
‡p = p-value
§For clarity, the soluble receptors are grouped with their respective 
ligand
*NE, Not EvaluableRespiratory Research 2007, 8:64 http://respiratory-research.com/content/8/1/64
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[54], however its role in COPD is not yet known. There are
increased numbers of granulocytes in the sputum and BAL
[38] in addition to small airways [55] of COPD patients,
leading others to speculate that granulocyte survival in the
lungs may be enhanced in COPD by mediators such as G-
CSF [38].
Another molecule identified is soluble Fas. Decreasing
concentrations of soluble Fas are associated with increas-
ing severity of diffusion impairment. Soluble Fas, a result
of alternative mRNA splicing, inhibits apoptosis by com-
petitively binding FasL and preventing its interaction with
the membrane bound Fas receptor [56,57]. The relation-
ship between systemic levels of soluble Fas and COPD is
unclear, as other smaller studies have shown variable
findings of either elevation or no difference compared
with controls [17-19]. Our results suggests that a systemic
imbalance of the anti-apoptotic factor soluble Fas occurs
in the setting of a pro-apoptotic environment of the lungs
in COPD.
The limitations of this present study include the size of the
cohort and its cross-sectional nature. The modest size, par-
ticularly the number of subjects with milder lung function
impairment (GOLD 0–1 stages), may limit the ability to
detect significant associations between systemic markers
and lung function impairment. Furthermore, we included
age, gender, pack years smoking history, current smoking,
inhaled corticosteroid use, systemic corticosteroid use and
statin use in the multivariate model. It is uncertain
whether adjustment for these covariates is appropriate.
Thus, we present both univariate and multivariate analy-
sis. We also recognize that the observed associations
between plasma concentrations of a protein and lung
function severity do not necessarily invoke a cause-effect
relationship. However, the findings of this study can serve
as the basis for a larger prospective cohort study examin-
ing a narrower profile of cytokines on a longitudinal basis.
Conclusion
Systemic inflammation has been increasingly recognized
in patients with COPD. CRP has been shown to be
increased in COPD [3,4], yet many other disease states
characterized by inflammation are associated with
increased CRP concentrations. Our data suggests that sys-
temic inflammation in a COPD cohort is also character-
ized by cytokines implicated in inflammatory cell
recruitment and airway remodeling. We show associa-
tions between plasma concentrations of chemokines and
IL-13 with increasing severity of disease, as measured by
% FEV1  or % DLCO. Increasing severity of diffusion
impairment is also associated with increasing G-CSF and
decreasing soluble Fas concentrations. We speculate that
disease characterized by disproportionate abnormalities
in DLCO may be associated with peripheral markers inde-
pendent of the FEV1. The biological plausibility of IL-13
and the discrete repertoire of inflammatory chemokines
identified in our model underscore the possibility to more
precisely characterize systemic inflammation of COPD.
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